| abstract |
The present invention relates to novel IL-15-IL-21 fusion polypeptides and uses thereof. According to the present invention, the IL-21-IL-15 fusion polypeptides of the present invention perform better functions than normal IL-21 and IL-15 cytokines and can induce NK cell activation and anti-tumor response. Rather, it can be manufactured in a simplified process due to the characteristic of a fusion polypeptide, and thus can be usefully used for mass production of high-quality cytokines at low cost, and thus has potential as a therapeutic agent for anti-cancer and immune diseases. |